Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.FLNA · Entity 7294 | Director · President & CEO | September 29, 2026 | October 01, 2026 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | August 05, 2020 | August 06, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date September 29, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 1,237,964 |
Reported balance
After 2026-09-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-29 · Purchase · Acquired 206,813 · Balance 1,237,964 F1: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.86 to $0.94 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 1,337,964 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Purchase · Acquired 100,000 · Balance 1,337,964 F2: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.91 to $0.93 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.86 to $0.94 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote.
F2: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.91 to $0.93 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote.
MIMEDX GROUP, INC.
Report date August 05, 2020 · Filed August 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares are held in trust | 3,338,135 |
Reported balance
After 2020-08-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-08-05 · Grant · Acquired 38,135 · Balance 3,338,135 F1: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the earlier of one year or the 2019 annual meeting of shareholders, and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the earlier of one year or the 2019 annual meeting of shareholders, and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3.
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,983,542 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 2,983,542 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 240,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 240,000 |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 10,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2019 Filed Sep 16, 2019 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 3,309 | $87.49 | $289,504.41 |
DisclosureSEC source: 0001209191-19-049553 · doc4.xml · nonDerivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187,065 Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 1,691 | $87.49 | $147,950.49 |
DisclosureSEC source: 0001209191-19-049553 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,183,756 F1 · price: The shares were purchased in transactions at prices ranging from $87.44 to $87.50, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 20, 2019 Filed Aug 20, 2019 21:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 5,000 | $99.32 | $496,592.50 |
DisclosureSEC source: 0001209191-19-046851 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,182,065 Read SEC document |
| August 14, 2019 Filed Aug 14, 2019 20:38 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 3,700 | $122.50 | $453,250.00 |
DisclosureSEC source: 0001209191-19-045929 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,177,065 Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 1,300 | $122.50 | $159,250.00 |
DisclosureSEC source: 0001209191-19-045752 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,173,365 Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,213 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016028 · doc4.xml · derivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Underlying: Common Stock · 3,213 shares Expires 2029-03-04 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016028 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,172,065 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 75,000 | $130.34 | $9,775,500.00 |
DisclosureSEC source: 0001209191-18-040091 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,432 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 15, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 4,820 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017786 · doc4.xml · derivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 Underlying: Common Stock · 4,820 shares Expires 2028-03-05 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 3,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017786 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,245,432 F1 · shares: Each restricted stock award represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020680 · doc4.xml · derivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020680 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,242,014 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.